-
Bank Ranking
Banks Ratios
Cement Statistics
Cement Ranking
Cement Ratios
Monetary and Economic Statistics
Oil, Gas and Fuel
Macro Economy
Consumer Spending
Inflation
Exports & Imports
Food Prices
Non Food Prices
Construction Materials
Petrochem. Ranking
Petrochem. Ratios
Retail Rankings
Retail Ratios
Grocery Ranking
Grocery Ratios
Top Growth
Dividend History
Almoosa Health 2024 net profit slips 5% to SAR 94.4M; Q4 at 8.9M
Almoosa Health Co. reported a net profit of SAR 49.4 million for 2024, a decrease of 5% from SAR 51.8 million in the year-earlier period.
Financials (Million Riyal)
| Item | 2023 | 2024 | Change |
|---|---|---|---|
| Revenues | 978.98 | 1,202.34 | 22.8 % |
| Gross Income | 307.00 | 371.72 | 21.1 % |
| Operating Income | 114.00 | 168.66 | 47.9 % |
| Net Income | 51.75 | 49.35 | (4.6 %) |
| Average Shares | 35.00 | 35.00 | - |
| Earnings Per Share before unusual items (Riyals) | 2.80 | 2.70 | (3.8 %) |
| EPS (Riyal) | 1.48 | 1.41 | (4.6 %) |
The profit drop was driven by a significant increase in depreciation and finance costs due to the major portion of the construction work-in-progress transferred to property and equipment.
Meanwhile, revenues increased by 22.8% due to a rise in the number of patients, accompanied by higher average revenues from outpatient visits, an expanded range of specialties, and a focus on specialized healthcare.
Medical services revenue rose by 12.3% to reach SAR 825.6 million, driven by an increase in inpatient numbers and outpatient visits at Almoosa Specialist Hospital, alongside the expansion of specialized care services.
Pharmaceutical services revenue increased by 38.3% to reach SAR 258.2 million, reflecting the growth in the number of patients receiving services.
Meanwhile, revenue from rehabilitation services reached SAR 118.5 million, a 108.6% increase, supported by full occupancy rates at Almoosa Rehabilitation Hospital during its first year of operation.
Gross profit increased by 21.1% in 2024 to SAR 371.7 million, driven by service expansion, improved operational efficiency, and the implementation of optimal pricing strategies, all contributing to enhanced overall profitability.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 37.8%, indicating increased operational efficiency.
Current Quarter Comparison (Million Riyal)
| Item | Q4 2023 | Q4 2024 | Change |
|---|---|---|---|
| Revenues | 272.81 | 332.11 | 21.7 % |
| Gross Income | 103.03 | 119.95 | 16.4 % |
| Operating Income | 27.92 | 69.69 | 149.6 % |
| Net Income | (26.22) | 8.96 | 134.2 % |
| Average Shares | 35.00 | 35.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.58 | 1.54 | 167.7 % |
| EPS (Riyal) | (0.75) | 0.26 | 134.2 % |
Q4 2024 net earnings amounted to SAR 8.96 million, against SAR 26.2 million loss in Q4 2023.
On a sequential basis, net profit fell 68% from SAR 27.93 million in Q3.
Total shareholders’ equity rose to SAR 1.33 billion by Dec. 31, 2024, compared to SAR 1.21 billion in the prior-year period.
Attached Documents
View other reports
Share Price
| Current | |
| Market Cap (M Riyal) | 5,032.48 |
| Enterprise Value (EV) (M Riyal) | 6,469.54 |
| Shares Outstanding ((M)) | 44.30 |
| Recurring EPS ( Riyal) (TTM) | 4.07 |
| Book Value (BV) ( Riyal) | 43.34 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E (TTM) | 27.91 |
| P/E (TTM) | 61.00 |
| Price/book | 2.62 |
| Dividend Yield (%) (Last Year) | 1.14 |
| Return on Average Assets (%) (TTM) | 2.2 |
| Return on Average Equity (%) (TTM) | 4.3 |
| EV/adj EBITDA | 21.52 |
| EV/Revenues | 4.19 |
Financial results (Million Riyal)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2024 | 277.16 | 19.1 % | 78.54 | 12.5 % | 30.64 | 10.7 % |
| Q2 2024 | 284.59 | 23.5 % | 75.17 | 10.0 % | 20.90 | (23.8 %) |
| Q3 2024 | 308.48 | 26.9 % | 98.07 | 48.9 % | 47.42 | 53.2 % |
| Q4 2024 | 332.11 | 21.7 % | 119.95 | 16.4 % | 69.69 | 149.6 % |
| 2024 | 1,202.34 | 22.8 % | 371.72 | 21.1 % | 168.66 | 47.9 % |
Profit Performance (Million Riyal)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2024 | 13.73 | (47.4 %) | 0.39 | - | 13.73 | 0.39 |
| Q2 2024 | (1.26) | (105.7 %) | (0.04) | - | (1.26) | (0.04) |
| Q3 2024 | 27.93 | (5.6 %) | 0.80 | - | 27.93 | 0.80 |
| Q4 2024 | 8.96 | 134.2 % | 0.26 | (45.07) | 54.03 | 1.54 |
| 2024 | 49.35 | (4.6 %) | 1.41 | (45.07) | 94.42 | 2.70 |
Profitability
| Period | Gross Margin | Adjusted EBITDA margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q4 2023 | 31.36 % | - | 10.03 % |
| 2023 | 31.36 % | 18.40 % | 10.03 % |
| Q1 2024 | 30.85 % | - | 8.38 % |
| Q2 2024 | 29.94 % | - | 5.77 % |
| Q3 2024 | 31.04 % | 17.91 % | 5.30 % |
| Q4 2024 | 30.92 % | 20.96 % | 7.85 % |
| 2024 | 30.92 % | 20.96 % | 7.85 % |
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2024 | 35.00 | 1.13 | 2.45 | 18.37 |
| Q2 2024 | 35.00 | 0.45 | 1.78 | 18.09 |
| Q3 2024 | 35.00 | 0.41 | 1.73 | 18.91 |
| Q4 2024 | 35.00 | 1.41 | 2.70 | 17.89 |
Multiple Ratios (End of Period Price)
| Period | P/E | Recurring P/E | Price/book |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q2 2024 | - | - | - |
| Q3 2024 | - | - | - |
| Q4 2024 | - | - | - |
Business Segments (Million Riyal)
Q4 2024
| Period | medical services | Pharmaceuticals | Rehabilitation |
|---|---|---|---|
| Q1 2024 | 198.18 | 58.67 | 20.30 |
| Q2 2024 | 172.08 | 70.77 | 41.74 |
| Q3 2024 | 227.66 | 63.78 | 17.04 |
| Q4 2024 | 227.64 | 65.02 | 39.45 |
Analysts Estimates (Million Riyal)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 62.30 | 8.96 |
Estimates vs Actual (Million Riyal)
| Item | Profit (Expected) | Profit (Actual) | Change | Profit Before Unusual Items | Change |
|---|---|---|---|---|---|
| SNB Capital | 62.30 | 8.96 | 54.03 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}